מדינה: אוסטרליה
שפה: אנגלית
מקור: APVMA (Australian Pesticides and Veterinary Medicines Authority)
PIMOBENDAN
Boehringer Ingelheim Animal Health Australia Pty. Ltd.
pimobendan(5mg/Cp)
ORAL CAPSULE
PIMOBENDAN PYRIDAZINONE Active 5.0 mg/Cp
100 Caps
VM - Veterinary Medicine
DOG | BITCH | CASTRATE | PUPPY
CARDIOVASCULAR SYSTEM
CONGESTIVE HEART FAILURE | DILATED CARDIOMYOPATHY | MITRAL AND/OR TRICUSPID REGUR | VALVULAR INSUFFICIENCY
Poison schedule: 4; Withholding period: WHP: N/A; Host/pest details: DOG: [CONGESTIVE HEART FAILURE, PRECLINICAL MYXOMATOUS MITRAL VALVE DISEASE]; DOG - LARGE: [CONGESTIVE HEART FAILURE, PRECLINICAL MYXOMATOUS MITRAL VALVE DISEASE]; For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation); also for treatment of preclinical DCM in large breed dogs.Should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where augmentation of cardiac output is not possible for functional or anatomical reasons.
Registered
2023-07-01
BOEHRINGER INGELHEIM PTY LIMITED, VETMEDICA DIVISION VETMEDIN 5 MG CAPSULES FOR DOGS 53562/105925 COMPANY NAME: PRODUCT NAME: APVMA APPROVAL NO: LABEL NAME: VETMEDIN 5 MG CAPSULES FOR DOGS SIGNAL HEADINGS: PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY CONSTITUENT STATEMENTS: Each capsule contains 5 mg pimobendan CLAIMS: Vetmedin® capsules are indicated for: The treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation). The treatment of preclinical DCM in large breed dogs. When used in cases of preclinical DCM in large breed dogs, pimobendan significantly prolonged the time to the onset of CHF or sudden death, and also resulted in prolongation of the time to death due to all causes. Doberman Pinscher dogs with preclinical DCM treated with pimobendan also demonstrated a significant reduction in Left Ventricular Internal Diameter in both systole and diastole (LVIDs/d) in response to therapy. NET CONTENTS: 100 capsules DIRECTIONS FOR USE: RESTRAINTS: CONTRAINDICATIONS: This product is contraindicated for use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not recommended for functional or anatomical reasons (e.g. aortic stenosis). PRECAUTIONS: Vetmedin® Capsules should only be administered to pregnant and lactating bitches if the expected therapeutic benefits overweigh the potential risk. RLP APPROVED Studies into the effect of pimobendan on the reproductive function of male dogs have not been conducted. The use in dogs not showing signs of cardiac disease is not recommended. In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. The pimobendan induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the B-antagonist propranolol. SIDE EFFECTS: A moderate positive chronotropic effect and vomiting may occur in rare cas קרא את המסמך השלם
CS: 1.7.2 Page: 1 MATERIAL SAFETY DATA SHEET 4 of Infosafe No™ LQ1I4 September 2012 ISSUED by BOEHRING Issue Date : VETMEDIN® CAPSULES FOR DOGS Product Name : Not classified as hazardous 1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER VETMEDIN® CAPSULES FOR DOGS PRODUCT NAME Boehringer Ingelheim Pty. Limited COMPANY NAME 78 Waterloo Rd North Ryde NSW 2113 Australia ADDRESS 1800 038 037 EMERGENCY TEL. Tel: 1800 038 037 Fax: +61 2 8875 8715 TELEPHONE/FAX NUMBER animalhealth.au@boehringer-ingelheim.com EMAIL Vetmedin® capsules are indicated for the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation). RECOMMENDED USE 2. HAZARDS IDENTIFICATION Not classified as hazardous NON-HAZARDOUS SUBSTANCE. NON-DANGEROUS GOODS. Hazard classification according to the criteria of NOHSC. Dangerous goods classification according to the Australia Dangerous Goods Code. HAZARD CLASSIFICATION 3. COMPOSITION/INFORMATION ON INGREDIENTS Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimentic, non-glycoside inotropic substance with potent vasodilatative properties. 1.25 mg capsule contains 1.25 mg pimobendan 2.5 mg capsule contains 2.5 mg pimobendan 5 mg capsule contains 5 mg pimobendan INFORMATION ON COMPOSITION NAME CAS PROPORTION INGREDIENTS Pimobendan (3(2H)-Pyridazinone, 4,5-dihydro-6-[2- (4-methoxyphenyl)-1H-be nzimidazol-5-yl]-5-meth yl-) 74150-27-9 <=2 % Ingredients determined not to be hazardous - Balance 4. FIRST AID MEASURES No special precautions required. However, if inhaled, remove affected person from contaminated area. Keep at rest until recovered. If symptoms persist seek medical attention. INHALATION Do not induce vomiting. Wash out mouth thoroughly with water. If symptoms develop seek medical attention. INGESTION Wash affected area thoroughly with soap and water. If symptoms develop seek medical attention. SKIN If in eyes, hold eyelids apart and flush the eyes continuously with running water. Contin קרא את המסמך השלם